NU 578 Unit 4 Exam Prep Document | 2026/2027 Edition | 250
Verified Questions
NU 578 Unit 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NU 578 Unit 4 at the University of South Alabama
features 250 verified questions and answers meticulously aligned with the 2026/2027 curriculum.
Designed to ensure mastery of advanced nursing concepts, this resource provides rationales for each
answer to facilitate deep understanding. Ideal for achieving a top score, the document reflects the latest
evidence-based practices and exam blueprints.
Key Features:
Advanced Pharmacology and Therapeutics
Pathophysiology of Complex Disease States
Evidence-Based Practice and Research Integration
Clinical Decision-Making and Diagnostic Reasoning
Patient Safety and Quality Improvement
Ethical and Legal Considerations in Advanced Practice
Updates for 2026:
- Updated to reflect 2026/2027 AACN Essentials and University of South Alabama curriculum changes
- Incorporated latest clinical practice guidelines from leading health organizations
- Revised rationales to include current evidence and research findings
- Added new questions on emerging topics such as telehealth and informatics
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This document serves as a definitive study resource for the NU 578 Unit 4 Examination at the University of South
Alabama, encompassing 250 meticulously verified questions and answers. The content is rigorously aligned with
the 2026/2027 academic year's learning objectives, emphasizing advanced nursing practice competencies. Each
question is accompanied by a detailed rationale that explains the correct answer and analyzes incorrect options,
fostering critical thinking and clinical reasoning. The material covers core areas including pharmacology,
pathophysiology, evidence-based practice, and ethical decision-making, ensuring comprehensive preparation.
Updated to reflect the latest guidelines and research, this guide is essential for students aiming to achieve a graded
A+ performance. The structured format allows for efficient study and self-assessment, with questions organized by
content area and difficulty. This resource not only prepares students for exam success but also reinforces
knowledge applicable to clinical practice.
Keywords:
NU 578, Unit 4 Exam, University of South Alabama, Advanced Nursing Practice, Verified Questions and Answers,
2026/2027 Update, Exam Preparation, A+ Guide
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct, along
with detailed explanations for each incorrect option (distractors). This format helps students understand underlying
concepts and avoid common mistakes, promoting deeper learning and retention.
Compliance Checklist:
Aligned with University of South Alabama NU 578 course objectives for 2026/2027
Incorporates latest AACN Essentials and national nursing standards
Page 1
, All answers verified by subject matter experts for accuracy
Rationales cite current evidence-based sources and guidelines
Content reviewed for clinical relevance and exam blueprint congruence
Designed to support achievement of a graded A+ performance
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Pharmacology 1-50 Pharmacokinetics, Pharmacodynamics, Drug 20%
Interactions, Adverse Effects, Prescribing
Principles
Pathophysiology 51-100 Cardiovascular, Respiratory, Renal, 20%
Endocrine, Neurological Systems
Evidence-Based Practice & 101-140 Research Designs, Statistical Analysis, 16%
Research Critical Appraisal, Implementation Science
Clinical Decision-Making 141-180 Diagnostic Reasoning, Differential 16%
Diagnosis, Clinical Guidelines, Patient
Management
Patient Safety & Quality 181-210 Error Prevention, Quality Improvement, 12%
Safety Culture, Root Cause Analysis
Ethics & Legal Issues 211-250 Informed Consent, Confidentiality, Advance 16%
Directives, Scope of Practice, Malpractice
Page 2
,Q1. A patient with severe aortic stenosis requires anticoagulation for atrial fibrillation. Which agent is most
appropriate considering the hemodynamic instability and need for rapid reversibility?
A. Warfarin with INR goal 2-3
B. Dabigatran
C. Heparin (unfractionated)
D. Apixaban
Correct Answer: C. Heparin (unfractionated)
Rationale: Unfractionated heparin is preferred in patients with severe aortic stenosis and hemodynamic instability
due to its short half-life, rapid reversibility with protamine, and ability to be titrated. Warfarin has a delayed onset
and narrow therapeutic window. Direct oral anticoagulants (DOACs) like dabigatran and apixaban are
contraindicated in severe valvular disease per current guidelines (e.g., AHA/ACC 2020).
Why Wrong:
A - Warfarin has a slow onset and requires frequent monitoring, unsuitable for acute hemodynamic instability.
B - Dabigatran is contraindicated in mechanical heart valves and severe valvular disease due to increased
thromboembolic risk.
D - Apixaban is not recommended for patients with severe aortic stenosis due to lack of evidence in this
population.
Reference: AHA/ACC 2020 Atrial Fibrillation Guidelines; Lehne, 2026, Ch. 34.
Q2. Which of the following mechanisms best explains the increased risk of QT prolongation when fluoxetine
is co-administered with ondansetron?
A. Inhibition of CYP2D6 by fluoxetine, increasing ondansetron levels
B. Additive serotonin syndrome risk
C. Both drugs block the hERG potassium channel
D. Fluoxetine reduces renal clearance of ondansetron
Correct Answer: C. Both drugs block the hERG potassium channel
Rationale: Both fluoxetine and ondansetron are known to block the hERG potassium channel, leading to additive
QT prolongation. While fluoxetine inhibits CYP2D6, ondansetron is primarily metabolized by CYP3A4, not
CYP2D6, so option A is incorrect. Serotonin syndrome is a risk with serotonergic drugs but does not directly cause
QT prolongation. Fluoxetine does not affect renal clearance of ondansetron.
Why Wrong:
A - Fluoxetine is a CYP2D6 inhibitor, but ondansetron is mainly metabolized by CYP3A4, making this
interaction clinically insignificant.
B - Serotonin syndrome does not directly prolong the QT interval; it is a separate safety concern.
D - Renal clearance is not a major pathway for ondansetron elimination; fluoxetine does not inhibit renal
transporters.
Reference: Lehne, 2026, Ch. 47; CredibleMeds.org, 2025.
Q3. A patient with chronic kidney disease stage 4 (eGFR 25 mL/min) requires treatment for hypertension.
Which antihypertensive agent requires the most cautious dose adjustment and monitoring due to risk of
hyperkalemia?
A. Amlodipine
B. Lisinopril
C. Metoprolol
D. Hydrochlorothiazide
Correct Answer: B. Lisinopril
Rationale: ACE inhibitors (like lisinopril) can cause hyperkalemia in advanced CKD due to reduced aldosterone
secretion. Amlodipine does not affect potassium levels. Metoprolol has minimal effect on potassium.
Hydrochlorothiazide is often ineffective when eGFR <30 mL/min and may cause hypokalemia, not hyperkalemia.
Page 3
, Why Wrong:
A - Amlodipine is a calcium channel blocker with no significant effect on potassium homeostasis.
C - Metoprolol is generally safe in CKD but does not cause hyperkalemia; it may mask hypoglycemia symptoms.
D - Hydrochlorothiazide is less effective in stage 4 CKD and tends to lower potassium, not raise it.
Reference: KDIGO 2021 Guidelines; Lehne, 2026, Ch. 28.
Q4. A patient on chronic lithium therapy presents with polyuria, polydipsia, and a serum lithium level of 0.8
mEq/L. Which of the following is the most likely cause of these symptoms?
A. Lithium-induced diabetes insipidus
B. Nephrogenic diabetes insipidus due to lithium
C. Psychogenic polydipsia
D. Hypercalcemia due to lithium
Correct Answer: B. Nephrogenic diabetes insipidus due to lithium
Rationale: Lithium commonly causes nephrogenic diabetes insipidus (NDI) by impairing the renal response to
antidiuretic hormone, leading to polyuria and polydipsia. Even therapeutic levels (0.8 mEq/L) can cause NDI.
Option A is redundant; NDI is the specific type. Psychogenic polydipsia is not lithium-related. Hypercalcemia is
not a typical adverse effect of lithium.
Why Wrong:
A - This is a general term; the specific mechanism is nephrogenic diabetes insipidus.
C - Psychogenic polydipsia is not caused by lithium and would not explain polyuria in a patient on lithium.
D - Lithium does not cause hypercalcemia; it may cause hyperparathyroidism but not directly hypercalcemia.
Reference: Lehne, 2026, Ch. 29; Stahl's Essential Psychopharmacology, 2025.
Q5. A patient with type 2 diabetes on metformin and insulin glargine is scheduled for coronary artery bypass
grafting (CABG). Which of the following is the most appropriate perioperative management of their diabetes
medications?
A. Continue metformin and hold insulin glargine on morning of surgery
B. Hold metformin 48 hours before surgery and continue insulin glargine at half dose
C. Discontinue both metformin and insulin glargine; start regular insulin sliding scale
D. Continue both metformin and insulin glargine as usual
Correct Answer: B. Hold metformin 48 hours before surgery and continue insulin glargine at half dose
Rationale: Metformin should be held 48 hours before surgery to reduce risk of lactic acidosis, especially with
potential renal impairment perioperatively. Insulin glargine is typically continued at a reduced dose (e.g., 50%) to
prevent hyperglycemia while avoiding hypoglycemia. Option A risks lactic acidosis from metformin. Option C may
lead to glycemic variability. Option D is unsafe due to metformin.
Why Wrong:
A - Continuing metformin perioperatively increases risk of lactic acidosis, especially if renal function
declines.
C - Discontinuing basal insulin entirely can cause severe hyperglycemia; a sliding scale alone is suboptimal.
D - Both medications should not be continued as usual; metformin must be held.
Reference: ADA Standards of Care 2026; Lehne, 2026, Ch. 45.
Q6. A patient with heart failure with reduced ejection fraction (HFrEF) is on sacubitril/valsartan. Which
monitoring parameter is most critical to assess before initiating this therapy?
A. Serum potassium and renal function
B. Liver function tests
C. Complete blood count
D. Hemoglobin A1c
Page 4
Verified Questions
NU 578 Unit 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NU 578 Unit 4 at the University of South Alabama
features 250 verified questions and answers meticulously aligned with the 2026/2027 curriculum.
Designed to ensure mastery of advanced nursing concepts, this resource provides rationales for each
answer to facilitate deep understanding. Ideal for achieving a top score, the document reflects the latest
evidence-based practices and exam blueprints.
Key Features:
Advanced Pharmacology and Therapeutics
Pathophysiology of Complex Disease States
Evidence-Based Practice and Research Integration
Clinical Decision-Making and Diagnostic Reasoning
Patient Safety and Quality Improvement
Ethical and Legal Considerations in Advanced Practice
Updates for 2026:
- Updated to reflect 2026/2027 AACN Essentials and University of South Alabama curriculum changes
- Incorporated latest clinical practice guidelines from leading health organizations
- Revised rationales to include current evidence and research findings
- Added new questions on emerging topics such as telehealth and informatics
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This document serves as a definitive study resource for the NU 578 Unit 4 Examination at the University of South
Alabama, encompassing 250 meticulously verified questions and answers. The content is rigorously aligned with
the 2026/2027 academic year's learning objectives, emphasizing advanced nursing practice competencies. Each
question is accompanied by a detailed rationale that explains the correct answer and analyzes incorrect options,
fostering critical thinking and clinical reasoning. The material covers core areas including pharmacology,
pathophysiology, evidence-based practice, and ethical decision-making, ensuring comprehensive preparation.
Updated to reflect the latest guidelines and research, this guide is essential for students aiming to achieve a graded
A+ performance. The structured format allows for efficient study and self-assessment, with questions organized by
content area and difficulty. This resource not only prepares students for exam success but also reinforces
knowledge applicable to clinical practice.
Keywords:
NU 578, Unit 4 Exam, University of South Alabama, Advanced Nursing Practice, Verified Questions and Answers,
2026/2027 Update, Exam Preparation, A+ Guide
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct, along
with detailed explanations for each incorrect option (distractors). This format helps students understand underlying
concepts and avoid common mistakes, promoting deeper learning and retention.
Compliance Checklist:
Aligned with University of South Alabama NU 578 course objectives for 2026/2027
Incorporates latest AACN Essentials and national nursing standards
Page 1
, All answers verified by subject matter experts for accuracy
Rationales cite current evidence-based sources and guidelines
Content reviewed for clinical relevance and exam blueprint congruence
Designed to support achievement of a graded A+ performance
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Pharmacology 1-50 Pharmacokinetics, Pharmacodynamics, Drug 20%
Interactions, Adverse Effects, Prescribing
Principles
Pathophysiology 51-100 Cardiovascular, Respiratory, Renal, 20%
Endocrine, Neurological Systems
Evidence-Based Practice & 101-140 Research Designs, Statistical Analysis, 16%
Research Critical Appraisal, Implementation Science
Clinical Decision-Making 141-180 Diagnostic Reasoning, Differential 16%
Diagnosis, Clinical Guidelines, Patient
Management
Patient Safety & Quality 181-210 Error Prevention, Quality Improvement, 12%
Safety Culture, Root Cause Analysis
Ethics & Legal Issues 211-250 Informed Consent, Confidentiality, Advance 16%
Directives, Scope of Practice, Malpractice
Page 2
,Q1. A patient with severe aortic stenosis requires anticoagulation for atrial fibrillation. Which agent is most
appropriate considering the hemodynamic instability and need for rapid reversibility?
A. Warfarin with INR goal 2-3
B. Dabigatran
C. Heparin (unfractionated)
D. Apixaban
Correct Answer: C. Heparin (unfractionated)
Rationale: Unfractionated heparin is preferred in patients with severe aortic stenosis and hemodynamic instability
due to its short half-life, rapid reversibility with protamine, and ability to be titrated. Warfarin has a delayed onset
and narrow therapeutic window. Direct oral anticoagulants (DOACs) like dabigatran and apixaban are
contraindicated in severe valvular disease per current guidelines (e.g., AHA/ACC 2020).
Why Wrong:
A - Warfarin has a slow onset and requires frequent monitoring, unsuitable for acute hemodynamic instability.
B - Dabigatran is contraindicated in mechanical heart valves and severe valvular disease due to increased
thromboembolic risk.
D - Apixaban is not recommended for patients with severe aortic stenosis due to lack of evidence in this
population.
Reference: AHA/ACC 2020 Atrial Fibrillation Guidelines; Lehne, 2026, Ch. 34.
Q2. Which of the following mechanisms best explains the increased risk of QT prolongation when fluoxetine
is co-administered with ondansetron?
A. Inhibition of CYP2D6 by fluoxetine, increasing ondansetron levels
B. Additive serotonin syndrome risk
C. Both drugs block the hERG potassium channel
D. Fluoxetine reduces renal clearance of ondansetron
Correct Answer: C. Both drugs block the hERG potassium channel
Rationale: Both fluoxetine and ondansetron are known to block the hERG potassium channel, leading to additive
QT prolongation. While fluoxetine inhibits CYP2D6, ondansetron is primarily metabolized by CYP3A4, not
CYP2D6, so option A is incorrect. Serotonin syndrome is a risk with serotonergic drugs but does not directly cause
QT prolongation. Fluoxetine does not affect renal clearance of ondansetron.
Why Wrong:
A - Fluoxetine is a CYP2D6 inhibitor, but ondansetron is mainly metabolized by CYP3A4, making this
interaction clinically insignificant.
B - Serotonin syndrome does not directly prolong the QT interval; it is a separate safety concern.
D - Renal clearance is not a major pathway for ondansetron elimination; fluoxetine does not inhibit renal
transporters.
Reference: Lehne, 2026, Ch. 47; CredibleMeds.org, 2025.
Q3. A patient with chronic kidney disease stage 4 (eGFR 25 mL/min) requires treatment for hypertension.
Which antihypertensive agent requires the most cautious dose adjustment and monitoring due to risk of
hyperkalemia?
A. Amlodipine
B. Lisinopril
C. Metoprolol
D. Hydrochlorothiazide
Correct Answer: B. Lisinopril
Rationale: ACE inhibitors (like lisinopril) can cause hyperkalemia in advanced CKD due to reduced aldosterone
secretion. Amlodipine does not affect potassium levels. Metoprolol has minimal effect on potassium.
Hydrochlorothiazide is often ineffective when eGFR <30 mL/min and may cause hypokalemia, not hyperkalemia.
Page 3
, Why Wrong:
A - Amlodipine is a calcium channel blocker with no significant effect on potassium homeostasis.
C - Metoprolol is generally safe in CKD but does not cause hyperkalemia; it may mask hypoglycemia symptoms.
D - Hydrochlorothiazide is less effective in stage 4 CKD and tends to lower potassium, not raise it.
Reference: KDIGO 2021 Guidelines; Lehne, 2026, Ch. 28.
Q4. A patient on chronic lithium therapy presents with polyuria, polydipsia, and a serum lithium level of 0.8
mEq/L. Which of the following is the most likely cause of these symptoms?
A. Lithium-induced diabetes insipidus
B. Nephrogenic diabetes insipidus due to lithium
C. Psychogenic polydipsia
D. Hypercalcemia due to lithium
Correct Answer: B. Nephrogenic diabetes insipidus due to lithium
Rationale: Lithium commonly causes nephrogenic diabetes insipidus (NDI) by impairing the renal response to
antidiuretic hormone, leading to polyuria and polydipsia. Even therapeutic levels (0.8 mEq/L) can cause NDI.
Option A is redundant; NDI is the specific type. Psychogenic polydipsia is not lithium-related. Hypercalcemia is
not a typical adverse effect of lithium.
Why Wrong:
A - This is a general term; the specific mechanism is nephrogenic diabetes insipidus.
C - Psychogenic polydipsia is not caused by lithium and would not explain polyuria in a patient on lithium.
D - Lithium does not cause hypercalcemia; it may cause hyperparathyroidism but not directly hypercalcemia.
Reference: Lehne, 2026, Ch. 29; Stahl's Essential Psychopharmacology, 2025.
Q5. A patient with type 2 diabetes on metformin and insulin glargine is scheduled for coronary artery bypass
grafting (CABG). Which of the following is the most appropriate perioperative management of their diabetes
medications?
A. Continue metformin and hold insulin glargine on morning of surgery
B. Hold metformin 48 hours before surgery and continue insulin glargine at half dose
C. Discontinue both metformin and insulin glargine; start regular insulin sliding scale
D. Continue both metformin and insulin glargine as usual
Correct Answer: B. Hold metformin 48 hours before surgery and continue insulin glargine at half dose
Rationale: Metformin should be held 48 hours before surgery to reduce risk of lactic acidosis, especially with
potential renal impairment perioperatively. Insulin glargine is typically continued at a reduced dose (e.g., 50%) to
prevent hyperglycemia while avoiding hypoglycemia. Option A risks lactic acidosis from metformin. Option C may
lead to glycemic variability. Option D is unsafe due to metformin.
Why Wrong:
A - Continuing metformin perioperatively increases risk of lactic acidosis, especially if renal function
declines.
C - Discontinuing basal insulin entirely can cause severe hyperglycemia; a sliding scale alone is suboptimal.
D - Both medications should not be continued as usual; metformin must be held.
Reference: ADA Standards of Care 2026; Lehne, 2026, Ch. 45.
Q6. A patient with heart failure with reduced ejection fraction (HFrEF) is on sacubitril/valsartan. Which
monitoring parameter is most critical to assess before initiating this therapy?
A. Serum potassium and renal function
B. Liver function tests
C. Complete blood count
D. Hemoglobin A1c
Page 4
